Anthony James Culverwell - Jan 1, 2023 Form 3 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Director
Signature
/s/ Anthony James Culverwell
Stock symbol
QNRX
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/3/2023, 08:38 AM
Next filing
Oct 30, 2023
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding QNRX Ordinary Shares 19.1M Jan 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding QNRX Share Option (right to buy) Jan 1, 2023 Ordinary Shares 64.3M $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents five thousand (5,000) ordinary shares of the Issuer.
F2 The option vests in four equal annual installments beginning on April 12, 2023.
F3 The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer represented by one (1) ADS, which evidences the grant of an option to buy 12,857.12 ADSs at the exercise price of $17.50 per ADS.